FDA Boxed Warning: Clopidogrel (Plavix®) Clinical Alert

Updated:Sep 4,2012
FDA Boxed Warning: Clopidogrel (Plavix®) Clinical Alert
  • Clinical antiplatelet effectiveness is reduced for poor metabolizers of clopidogrel. 
  • Genetic tests are available to identify poor metabolizers.
  • Emerging role of genetic testing in clopidogrel treatment decisions

Read full clinical alert in Circulation

Editorial: Responding to the Clopidogrel Warning by the US Food and Drug Administration: Real Life Is Complicated
by Dan M. Roden, M.D., and Alan R. Shuldiner, M.D.

Supporting Materials

Other AHA Statements on Anticoagulation


Professional Online Network

Connect with over 30,000 heart and stroke professionals.